Ophthalmic Plastic & Reconstructive Surgery, University of Health Sciences Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
Ophthalmology Department, Memorial Hospital, Faculty of Medicine, Arel University.
Arq Bras Oftalmol. 2023 Apr 3;87(5):e20220151. doi: 10.5935/0004-2749.2022-0151. eCollection 2023.
A 42-year-old woman presented with bilateral proptosis, chemosis, leg pain, and vision loss. Orbital, chorioretinal, and multi-organ involvement of Erdheim-Chester disease, a rare non-Langerhans histiocytosis, with a negative BRAF mutation was diagnosed based on clinical, radiological, and pathological findings. Interferon-alpha-2a (IFNα-2a) was started, and her clinical condition improved. However, 4 months later, she had vision loss with a history of IFNα-2a cessation. The same therapy was administered, and her clinical condition improved. The Erdheim-Chester disease is a rare chronic histiocytic proliferative disease that requires a multidisciplinary approach and can be fatal if left untreated because of multisystemic involvements.
一位 42 岁女性因双侧眼球突出、球结膜水肿、腿部疼痛和视力丧失就诊。根据临床、影像学和病理学检查结果,诊断为 Erdheim-Chester 病(一种罕见的非朗格汉斯细胞组织细胞增生症),该疾病累及眼眶、脉络膜和多个器官,且 BRAF 突变阴性。给予干扰素-α-2a(IFNα-2a)治疗后,患者的临床状况有所改善。然而,4 个月后,患者因停止 IFNα-2a 治疗而出现视力丧失。再次给予相同的治疗后,患者的临床状况改善。Erdheim-Chester 病是一种罕见的慢性组织细胞增生性疾病,需要多学科治疗,如果不治疗,由于多系统受累,该病可能致命。